Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4384 The efficacy of combination of temozolomide and capecitabine for neuroendocrine tumours: A real-world comparison of outcomes in Alberta, Canada – Patients treated from 2011-2021

Introduction: The combination of capecitabine and temozolomide (CAPTEM) showed PFS benefits in pancreatic neuroendocrine tumours (PNETs).

Conference:

Presenting Author:

Authors: Aleksi A, Malek H, Husi P, Halperin H, White-Gloria C,

Keywords: captem, neuroendocrine tumour, endocrine tumour, progression-free survival, overall survival,

#3533 Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial

Introduction: TALENT phase II trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, no predictive biomarker has been associated to antiangiogenic treatment benefit to date.

Conference:

Presenting Author: Garcia-Alvarez A

Authors: Garcia Alvarez A, Hernando J, Jimenez-Valero G, Martinez A, Fazio N,

Keywords: Lenvatinib, Angiogenesis, Ang2, VEGFR2,

#3528 Computerized tomography (CT)-based hepatic radiomics phenotypes associate with response to anti-angiogenics in neuroendocrine tumors (NETs): A subanalysis from the phase II TALENT clinical trial

Introduction: The phase II TALENT clinical trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, the role of radiomic predictive biomarkers of response to antiangiogenic drugs remain unknown.

Conference:

Presenting Author: Garcia Alvarez A

Authors: Garcia Alvarez A, Hernando J, Ligero M, Delgado E, Ibrahim T,

Keywords: Lenvatinib, Radiomics,

#1841 The Characteristics and Survivals of Gastrointestinal Neuroendocrine Tumors, A Single Center Experience from Developing Country

Introduction: Gastrointestinal neuroendocrine tumors (GINETs) are a heterogeneous group of tumors with variable behaviors. We analyzed baseline characteristics and outcomes of GINETs and impact of the tumor grade on the overall survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Ali J, Qubtia M, Hassan A, Ahmad U,

Keywords: Neuroendocrine tumors, retrospective studies,

#882 Gene Expression Characterization of Gastroenteropancreatic Neuroendocrine Tumors [GEPNETS: Gastrointestinal and Pancreatic NETs (GINETs and pNETs)] and Their Correlation with Clinical Factors and Tumor Behavior

Introduction: GEP-NETs are a heterogenous group of tumors with different molecular backgrounds and clinical outcome.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Martínez-Fuentes A

Authors: Díaz Pérez J, García-Carbonero R, Villabona C, Capdevila J, Jiménez-Fonseca P,

Keywords: sst4, RET, angiogenesis, GEP-NET,